Avianca Cargo has obtained Good Distribution Practice (GDP) certification for its operations in Madrid and Barcelona, the carrier's gateway stations in Spain and two of its principal European points for transatlantic freighter and belly capacity.

The certification applies to the airline's handling of pharmaceutical and life-science cargo at both airports. GDP certification is the industry benchmark for pharmaceutical logistics: it audits temperature control, handling procedures, documentation and staff training against standards set out for the distribution of medicinal products for human use. Airlines, ground handlers and freight forwarders seek the certification because pharmaceutical shippers and their logistics providers increasingly require it as a condition of awarding temperature-sensitive freight.

For Avianca Cargo, the Madrid and Barcelona certifications extend a credentials portfolio that the airline has built around its network linking Latin America with Europe and the Americas. Spain is the carrier's European anchor: Madrid has long functioned as Avianca's principal transatlantic hub for belly cargo carried in partnership on passenger services, with Barcelona serving as a secondary distribution point. The GDP approvals at both stations position the airline to compete for pharmaceutical traffic moving between European origins and Latin American destinations, a lane where temperature-controlled capacity is in persistent demand and where certified competitors have been steadily expanding.

The commercial logic is straightforward. Pharmaceutical cargo ranks among the highest-yielding commodities in air freight, and shippers in the sector consolidate volumes with carriers that can demonstrate end-to-end compliance. An airline without GDP-certified stations at its gateways is effectively excluded from tenders issued by large pharmaceutical manufacturers and their logistics integrators. By certifying both Madrid and Barcelona, Avianca Cargo closes that gap at the two Spanish points where European pharma traffic would most plausibly connect onto its Latin American network.

The certification also carries operational consequences. GDP compliance requires validated temperature-control procedures at acceptance, storage and loading; calibrated monitoring equipment; documented contingency handling for excursions; and recurrent training for staff involved in pharmaceutical shipments. Those requirements translate into process discipline that shippers can audit, and they impose costs in equipment, training and quality management that an airline recovers only if it wins and retains pharma volume.

Avianca Cargo's move comes as competition for pharmaceutical air freight intensifies on the Europe–Latin America corridor. Latin American carriers, European network airlines and freighter operators alike have invested in cool-chain facilities and certifications over the past several years, and GDP or equivalent CEIV Pharma credentials have become the entry ticket. Avianca Cargo itself has pursued pharma certifications across its network as part of a broader strategy to shift its cargo mix toward higher-value commodities rather than relying on general freight volumes.

The certification at the Spanish stations does not, on its own, guarantee share. What it does is remove a qualification barrier and signal to pharmaceutical shippers and forwarders that Avianca Cargo's Madrid and Barcelona operations meet the handling standards their products require. The competitive test will come in the tenders that follow: whether the carrier converts certified capability into contracted tonnage on its transatlantic lanes.

With GDP certification now in place at both of its Spanish gateways, Avianca Cargo is positioned to pursue pharmaceutical contracts across its Europe–Latin America network, and the carrier's ability to build pharma tonnage on those lanes will be the measure of the investment.